Mesoblast (MESO)

• Market cap: $2.13B
• 1 day: -0.72%
• 5 days: -1.48%
• 1 month: 3.68%
• 3 months: 4.2%
• 6 months: 39.46%
• Year to date: -19.41%
• 1 year: 83.33%
• 5 years: -23.81%
• 10 years: 2.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Employees: 81